These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 34348004)
1. Could Harnessing Natural Killer Cell Activity Be a Promising Therapy for Prostate Cancer? Wu J Crit Rev Immunol; 2021; 41(2):101-106. PubMed ID: 34348004 [TBL] [Abstract][Full Text] [Related]
2. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130 [TBL] [Abstract][Full Text] [Related]
3. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8 Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833 [TBL] [Abstract][Full Text] [Related]
4. Simultaneous Engagement of Tumor and Stroma Targeting Antibodies by Engineered NK-92 Cells Expressing CD64 Controls Prostate Cancer Growth. Hintz HM; Snyder KM; Wu J; Hullsiek R; Dahlvang JD; Hart GT; Walcheck B; LeBeau AM Cancer Immunol Res; 2021 Nov; 9(11):1270-1282. PubMed ID: 34452926 [TBL] [Abstract][Full Text] [Related]
5. Natural killer cells: the next wave in cancer immunotherapy. Chen X; Jiang L; Liu X Front Immunol; 2022; 13():954804. PubMed ID: 35967421 [TBL] [Abstract][Full Text] [Related]
6. Harnessing NK Cells for Cancer Treatment. Minetto P; Guolo F; Pesce S; Greppi M; Obino V; Ferretti E; Sivori S; Genova C; Lemoli RM; Marcenaro E Front Immunol; 2019; 10():2836. PubMed ID: 31867006 [TBL] [Abstract][Full Text] [Related]
7. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy. Shaver KA; Croom-Perez TJ; Copik AJ Front Immunol; 2021; 12():679117. PubMed ID: 33995422 [TBL] [Abstract][Full Text] [Related]
9. Harnessing Natural Killer Cell Function for Genitourinary Cancers. Bhardwaj N; Farkas AM; Gul Z; Sfakianos JP Urol Clin North Am; 2020 Nov; 47(4):433-442. PubMed ID: 33008494 [TBL] [Abstract][Full Text] [Related]
10. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer. Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A Cells; 2020 Jun; 9(6):. PubMed ID: 32498368 [TBL] [Abstract][Full Text] [Related]
11. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). Pachynski RK; Morishima C; Szmulewitz R; Harshman L; Appleman L; Monk P; Bitting RL; Kucuk O; Millard F; Seigne JD; Fling SP; Maecker HT; Duault C; Ramchurren N; Hess B; D'Amico L; Lacroix A; Kaiser JC; Morre M; Grégoire A; Cheever M; Yu EY; Fong L J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452927 [TBL] [Abstract][Full Text] [Related]
12. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells. Kim N; Kim HS Front Immunol; 2018; 9():2041. PubMed ID: 30250471 [TBL] [Abstract][Full Text] [Related]
13. Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors. Kim N; Lee DH; Choi WS; Yi E; Kim H; Kim JM; Jin HS; Kim HS BMB Rep; 2021 Jan; 54(1):44-58. PubMed ID: 33298244 [TBL] [Abstract][Full Text] [Related]
14. Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy. Prokhnevska N; Emerson DA; Kissick HT; Redmond WL Adv Exp Med Biol; 2019; 1210():121-147. PubMed ID: 31900908 [TBL] [Abstract][Full Text] [Related]
15. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors. Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360 [TBL] [Abstract][Full Text] [Related]
16. Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer. Bödder J; Zahan T; van Slooten R; Schreibelt G; de Vries IJM; Flórez-Grau G Front Immunol; 2020; 11():631713. PubMed ID: 33679726 [TBL] [Abstract][Full Text] [Related]
17. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. Lundholm M; Schröder M; Nagaeva O; Baranov V; Widmark A; Mincheva-Nilsson L; Wikström P PLoS One; 2014; 9(9):e108925. PubMed ID: 25268476 [TBL] [Abstract][Full Text] [Related]
18. Ex vivo expansion of CD8+CD56+ and CD8+CD56- natural killer T cells specific for MUC1 mucin. Wajchman HJ; Pierce CW; Varma VA; Issa MM; Petros J; Dombrowski KE Cancer Res; 2004 Feb; 64(3):1171-80. PubMed ID: 14871854 [TBL] [Abstract][Full Text] [Related]
19. Epigenetic modulation and prostate cancer: Paving the way for NK cell anti-tumor immunity. Dos Reis FD; Jerónimo C; Correia MP Front Immunol; 2023; 14():1152572. PubMed ID: 37090711 [TBL] [Abstract][Full Text] [Related]